Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies (NCT01461538)
This is an open-label, multicenter, phase II clinical trial to evaluate the antitumor activity of the antibody-drug conjugate (ADC) brentuximab vedotin (also known as SGN-035) as a single agent in patients with CD30-positive nonlymphomatous malignancies.
This trial is sponsored by Seattle Genetics. 
- Condition: Nonlymphomatous Malignancies
- Phase: II
- Enrollment: 84
- Start: October 2011
- Completion: December 2014
- Last verified: May 2015
Last Editorial review: July 2, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.